Virdante has not disclosed which indication it will pursue first to take its sialylated IVIG product through clinical proof of concept...Pronota, which develops protein biomarker diagnostics, is using the proceeds to develop its lead program in acute heart failure to full clinical proof of concept.

The Phase Ib trial was a pilot proof-of-concept study conducted in the U.S

Once an asset shows therapeutic potential at proof of concept, Flexion either returns the asset to the partner for subsequent development, or advances it to commercialization independently

RLY5016 has completed two Phase I trials and shown proof of concept in a Phase IIa trial

Vantia Therapeutics, of Southampton, UK, said its oral small-molecule drug, VA111913, entered Phase II proof-of-concept trials in dysmenorrhea, or painful menstruation

Vertex Pharmaceuticals Inc., of Cambridge, Mass., plans to initiate a Phase II proof-of-concept trial for VX-509, a highly selective inhibitor of Janus kinase 3

Following a verbal clinical hold notice from the FDA, the agency gave Repros a written notice outlining the specific clinical deficiency and the information that would be needed to resolve the full clinical hold

In October 2008, the San Carlos, Calif.-based company reported proof-of-concept data in a Phase I trial of ALV003...Dawson James Securities acted as exclusive placement agent.

Initiation of the clinical trial has triggered an undisclosed milestone payment under the agreement...Merck also is reviewing clinical data for migraine compound MK-0974 (telcagepant), which is in Phase III trials in preparation for discussions with regulatory agencies later this year...The study is the second neural stem cell clinical trial for neurodegenerative diseases to be conducted in the U.S. A Phase I trial using the same type of neural stem cells was completed in January, with reported

The results represented the first demonstration of clinical efficacy for the class of resolvin compounds and suggested that resolvins have the potential to treat a broad range of inflammatory diseases, Resolvyx said...Seattle Genetics Inc., of Bothell, Wash., completed enrollment of its pivotal clinical trial of brentuximab vedotin (SGN-35) for relapsed and refractory Hodgkin lymphoma...Valeant Pharmaceuticals International Inc., of Aliso Viejo, Calif., disclosed preliminary results from its Phase IIa

The proof-of-concept study will test 4SC-201 in combination with Nexavar (sorafenib, Onyx Pharmaceuticals Inc. and Bayer HealthCare) in the 15-patient first arm, while a second arm will involve 15 patients who discontinue Nexavar treatment prior to enrollment to receive 4SC-201 as a monotherapy

The company now plans to initiate a proof-of-concept study in patients with photosensitive epilepsy

BrainCells Inc., of San Diego, reported positive results from the first clinical proof-of-concept study of BCI-952, a combination of low-dose buspirone and melatonin, for the treatment of major depressive disorder

QRxPharma Ltd., of Sydney, Australia, has begun a Phase II comparative proof-of-concept study to evaluate the efficacy and safety of MoxDuo I.V. (intravenous morphine and oxycodone) vs. I.V

Limerick's second-generation of activators compounds is superior to the initial program, which provided proof-of-concept in three clinical studies in the opioid (pain) and immunosuppressant area

Yet Haffar noted that, like many other small biotechs, Presidio has had to make some tough decisions and prioritize, so for now most of the emphasis is on reaching clinical proof of concept with PPI-461 for HCV

Stephen Parker, a partner in Celtic Pharma, said that assuming all milestones are met, the money is sufficient to take the three products through to clinical proof of concept and partnering

Its second clinical stage product, CP-4126, comprises the same lipid moiety attached to gemcitabine, currently marketed (though soon to go off patent) as Gemzar by Indianapolis-based Eli Lilly and Co...Also ongoing is a preclinical proof-of-concept study of CP-4200, a derivative of azacitidine, the myelodysplastic syndrome marketed as Vidaza by Celgene Corp., of Summit, N.J

ExonHit Therapeutics, of Paris, said clinical testing of EHT 0202, its lead therapeutic compound in Alzheimer's disease, has completed final patient dosing for the Phase IIa proof-of-concept trial